New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer
Bonnie Gillis | December 05, 2012
Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.
Results of a multinational phase III clinical trial involving women with breast cancer in 27 countries found that adjuvant therapy with the aromatase inhibitor letrozole following surgical excision conferred greater survival benefit than tamoxifen.
Results of a multinational phase III clinical trial involving women with breast cancer in 27 countries found that adjuvant therapy with the aromatase inhibitor letrozole following surgical excision conferred greater survival benefit than tamoxifen.
Multiple studies presented at the San Antonio Breast Cancer Symposium report encouraging findings on the role of aromatase inhibitors in treating postmenopausal women with early-stage estrogen receptor-positive breast cancer.
